Medivation (MDVN) PT Raised to $52 at Jefferies
Get Alerts MDVN Hot Sheet
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Jefferies analyst Biren Amin raised his price target on Medivation (NASDAQ: MDVN) to $52.00 (from $39.00) following a Xtandi survey but maintained a Hold rating.
Amin commented, "We surveyed 50 physicians on current/projected Xtandi use and the trend appears to show increasing usage in most mCRPC populations especially after noting the STRIVE/TERRAIN data. Another key observation is duration of therapy for Xtandi extends meaningfully,further reversing a shortening duration seen in previous surveys. These conclusions drive our raising of expectations for Xtandi."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $57.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- QuantumScape (QS) PT Lowered to $6 at Truist Securities
- Comerica (CMA) PT Raised to $54 at Piper Sandler
- Intuitive Surgical (ISRG) PT Raised to $375 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, FDARelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!